Anti-Nerve Growth Factor Developers Face Go/No-Go Recommendation From Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA sets March 12 as date for the Arthritis Advisory Committee to weigh in on whether safety issues are a barrier to development of anti-NGF compounds as analgesics. Developers’ trials are on hold while FDA considers the potential for adverse effects seen in osteoarthritis patients taking the monoclonal antibodies for pain.
You may also be interested in...
Anti-NGFs Advisory Committee Postponed As FDA Reviews New Information
The agency is assessing safety signals for the biologics, which are being developed for chronic pain.
Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications
The three companies' decisions were spurred by concerns about potential for the bone disorder avascular necrosis.
No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials
Safety concerns require Pfizer to scupper two additional studies of its Phase III tanezumab, casting doubt on an entire class of new pain drugs.